Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that imaGenes GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for Comparative Genomic Hybridization (CGH). imaGenes is a solution provider for functional genomics and proteomics with a comprehensive portfolio of highquality services for molecular life sciences. This is the third Roche NimbleGen certification for imaGenes to provide service for NimbleGen arrays. This follows the successful certification for ChIPchip in December 2009 and DNA methylation analysis in February 2010, and makes imaGenes the first service provider in Europe with the CGH certification.
With this announcement, imaGenes now offers CGH using the comprehensive array workflow from Roche NimbleGen, which includes the NimbleGen MS 200 Microarray Scanner, arrays, reagents and software. CGH is an important arraybased tool that allows for the detection of chromosomal abnormalities, copy number variations, and specific breakpoints at much higher resolution over conventional methods. The genomewide and disease associated region focused analysis on these types of chromosomal changes allows for a clearer understanding of the genome and how these changes can impact disease. This indepth information will help researchers to develop future methods and tools to better diagnose and treat these diseases.
"The comprehensive portfolio of Roche NimbleGen certified services enables imaGenes to offer any functional DNA analysis to its customers in consistent high quality. Roche NimbleGen is our reliable partner en route to become the premier service provider for both biomarker development and clinical research applications," says Dr. Johannes Maurer, Director Genomic Products & Marketing at imaGenes.
"Roche NimbleGen is extremely pleased to partner with a company that has such a strong commitment to building up their service business and expanding the solutions they offer to the genomics market. We are excited about the addition to their service portfolio of our cuttingedge NimbleGen CGH arrays and the establishment of our first CGH CSP in Europe. imaGenes has once again demonstrated their technical expertise and business acumen, this time in an area as dynamic and fast growing as the array based copy number detection market," adds Dr. Frank Pitzer, CEO for Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
With this announcement, imaGenes now offers CGH using the comprehensive array workflow from Roche NimbleGen, which includes the NimbleGen MS 200 Microarray Scanner, arrays, reagents and software. CGH is an important arraybased tool that allows for the detection of chromosomal abnormalities, copy number variations, and specific breakpoints at much higher resolution over conventional methods. The genomewide and disease associated region focused analysis on these types of chromosomal changes allows for a clearer understanding of the genome and how these changes can impact disease. This indepth information will help researchers to develop future methods and tools to better diagnose and treat these diseases.
"The comprehensive portfolio of Roche NimbleGen certified services enables imaGenes to offer any functional DNA analysis to its customers in consistent high quality. Roche NimbleGen is our reliable partner en route to become the premier service provider for both biomarker development and clinical research applications," says Dr. Johannes Maurer, Director Genomic Products & Marketing at imaGenes.
"Roche NimbleGen is extremely pleased to partner with a company that has such a strong commitment to building up their service business and expanding the solutions they offer to the genomics market. We are excited about the addition to their service portfolio of our cuttingedge NimbleGen CGH arrays and the establishment of our first CGH CSP in Europe. imaGenes has once again demonstrated their technical expertise and business acumen, this time in an area as dynamic and fast growing as the array based copy number detection market," adds Dr. Frank Pitzer, CEO for Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
